Published in Ann N Y Acad Sci on January 01, 2000
Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev (2011) 5.20
Axonal transport defects in neurodegenerative diseases. J Neurosci (2009) 2.74
Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A (2009) 2.61
C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet (2008) 2.03
Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. Hum Mol Genet (2013) 1.94
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain (2008) 1.72
Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol (2003) 1.67
Dopamine release in the basal ganglia. Neuroscience (2011) 1.67
Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci (2009) 1.66
Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse (2007) 1.41
Unfoldomics of human diseases: linking protein intrinsic disorder with diseases. BMC Genomics (2009) 1.41
Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol Aging (2008) 1.41
Parkinson's disease and α-synuclein expression. Mov Disord (2011) 1.34
Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol (2009) 1.27
Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx (2005) 1.22
Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. Nat Chem Biol (2015) 1.22
Inflammation in the early stages of neurodegenerative pathology. J Neuroimmunol (2011) 1.21
Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol (2013) 1.20
MicroRNA-7a regulates pancreatic β cell function. J Clin Invest (2014) 1.18
Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc Natl Acad Sci U S A (2012) 1.14
Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol Brain (2010) 1.13
Protein disorder in the human diseasome: unfoldomics of human genetic diseases. BMC Genomics (2009) 1.11
A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics (2012) 1.11
Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One (2013) 1.10
Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci (2012) 1.10
Amyloidogenesis of natively unfolded proteins. Curr Alzheimer Res (2008) 1.08
Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther (2013) 1.06
The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease. Neurogenetics (2005) 1.06
Explaining the structural plasticity of α-synuclein. J Am Chem Soc (2011) 1.01
Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones. J Biol Chem (2010) 1.00
What macromolecular crowding can do to a protein. Int J Mol Sci (2014) 0.96
Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. Mol Neurodegener (2009) 0.95
Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model. Mol Neurodegener (2010) 0.95
Glia and alpha-synuclein in neurodegeneration: A complex interaction. Neurobiol Dis (2015) 0.93
Animal models of Parkinson's disease: a gateway to therapeutics? Neurotherapeutics (2014) 0.93
Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze? Neurotox Res (2008) 0.91
Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Parkinsons Dis (2013) 0.91
Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease. Neuroscience (2012) 0.90
Mechanism of copper(II)-induced misfolding of Parkinson's disease protein. Sci Rep (2011) 0.89
Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity. Front Aging Neurosci (2014) 0.88
Advances with microRNAs in Parkinson's disease research. Drug Des Devel Ther (2013) 0.87
Microtubule depolymerization suppresses alpha-synuclein accumulation in a mouse model of multiple system atrophy. Am J Pathol (2009) 0.87
Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice. Mol Neurodegener (2015) 0.87
Structures of segments of α-synuclein fused to maltose-binding protein suggest intermediate states during amyloid formation. Protein Sci (2011) 0.86
Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death. Front Neuroanat (2014) 0.86
Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. CNS Neurol Disord Drug Targets (2012) 0.85
Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci (2011) 0.85
Suppression of α-synuclein toxicity and vesicle trafficking defects by phosphorylation at S129 in yeast depends on genetic context. Hum Mol Genet (2012) 0.85
Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases. Int J Alzheimers Dis (2012) 0.85
Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background. Eur J Neurosci (2011) 0.84
Neurodegenerative changes initiated by presynaptic dysfunction. Transl Neurodegener (2013) 0.84
The potential for transition metal-mediated neurodegeneration in amyotrophic lateral sclerosis. Front Aging Neurosci (2014) 0.84
Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease. BMC Neurosci (2009) 0.83
Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy. Pathobiol Aging Age Relat Dis (2015) 0.83
MicroRNAs in Neurotoxicity. J Toxicol (2012) 0.83
α-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies. Int J Alzheimers Dis (2012) 0.83
Parkinson's disease. Subcell Biochem (2012) 0.82
Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein. Neurobiol Dis (2014) 0.81
Preparation and Characterization of Stable α-Synuclein Lipoprotein Particles. J Biol Chem (2016) 0.80
G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons. J Neurosci (2016) 0.80
Prevalence and timeline of nonmotor symptoms in idiopathic rapid eye movement sleep behavior disorder. J Neurol (2015) 0.80
Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies. Perspect Medicin Chem (2008) 0.80
Formation of cholesterol ozonolysis products in vitro and in vivo through a myeloperoxidase-dependent pathway. J Lipid Res (2010) 0.80
Functionally different α-synuclein inclusions yield insight into Parkinson's disease pathology. Sci Rep (2016) 0.80
Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies. Expert Opin Ther Targets (2015) 0.80
Autonomic dysfunction and plasticity in micturition reflexes in human α-synuclein mice. Dev Neurobiol (2012) 0.80
Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci U S A (2016) 0.79
Mechanisms of action of brain insulin against neurodegenerative diseases. J Neural Transm (Vienna) (2014) 0.79
Efficient construction of disordered protein ensembles in a Bayesian framework with optimal selection of conformations. Pac Symp Biocomput (2012) 0.79
Infectivity versus Seeding in Neurodegenerative Diseases Sharing a Prion-Like Mechanism. Int J Cell Biol (2013) 0.79
Photo-activity induced by amyloidogenesis. Protein Sci (2007) 0.79
Exploring the accessible conformations of N-terminal acetylated α-synuclein. FEBS Lett (2013) 0.79
β-Synuclein suppresses both the initiation and amplification steps of α-synuclein aggregation via competitive binding to surfaces. Sci Rep (2016) 0.78
A network view on Parkinson's disease. Comput Struct Biotechnol J (2013) 0.78
Drug targets from genetics: α-synuclein. CNS Neurol Disord Drug Targets (2011) 0.78
A novel resource for studying function and dysfunction of α-synuclein: mouse lines for modulation of endogenous Snca gene expression. Sci Rep (2015) 0.77
Resting state in Parkinson's disease dementia and dementia with Lewy bodies: commonalities and differences. Int J Geriatr Psychiatry (2015) 0.77
Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies. J Neurol (2016) 0.76
[Postmortal diagnosis of Parkinson's disease]. Pathologe (2005) 0.76
Neuron-astrocyte interactions in neurodegenerative diseases: Role of neuroinflammation. Clin Exp Neuroimmunol (2015) 0.76
Role of neurotoxicants and traumatic brain injury in α-synuclein protein misfolding and aggregation. Brain Res Bull (2016) 0.76
Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization. Sci Rep (2017) 0.75
Review: Multiple system atrophy: emerging targets for interventional therapies. Neuropathol Appl Neurobiol (2016) 0.75
α-synuclein folds: the cards are on the table. Nat Struct Mol Biol (2016) 0.75
Clinical variations in Parkinson's disease patients with or without REM sleep behaviour disorder: a meta-analysis. Sci Rep (2017) 0.75
Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain. Acta Neuropathol Commun (2017) 0.75
Protein aggregation: close encounters of the greasy kind. Nat Chem Biol (2015) 0.75
Metallothionein, Copper and Alpha-Synuclein in Alpha-Synucleinopathies. Front Neurosci (2017) 0.75
Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease. Sci Rep (2017) 0.75
Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. Neurotherapeutics (2016) 0.75
Rapid Eye Movement Sleep Homeostatic Response: A Potential Marker for Early Detection of Parkinson's Disease. J Alzheimers Dis Parkinsonism (2016) 0.75
Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism. F1000Res (2017) 0.75
A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies. PLoS One (2017) 0.75
Subventricular zone under the neuroinflammatory stress and Parkinson's disease. Cell Mol Neurobiol (2011) 0.75
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A (1998) 8.41
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol (1999) 4.98
Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A (2000) 3.86
Identification of two distinct synucleins from human brain. FEBS Lett (1994) 3.61
Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 3.45
Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett (1998) 3.26
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res (1994) 3.26
The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J (1992) 3.04
Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol (1998) 2.73
The mas oncogene encodes an angiotensin receptor. Nature (1988) 2.53
Tau protein pathology in neurodegenerative diseases. Trends Neurosci (1998) 2.37
Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem (1998) 2.32
Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett (1998) 2.26
Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett (1999) 2.05
A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res (2000) 1.97
Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci U S A (1996) 1.94
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (2000) 1.92
Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ (1998) 1.92
Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci U S A (1997) 1.89
A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett (1999) 1.88
High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet (1999) 1.87
Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene (1999) 1.86
Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol (2015) 1.86
Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis (2000) 1.84
Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol (1994) 1.84
Synergistic activation of SAPK1/JNK1 by two MAP kinase kinases in vitro. Curr Biol (1999) 1.81
Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett (1998) 1.79
Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J (1995) 1.77
Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A (1994) 1.74
Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. Proc Natl Acad Sci U S A (1999) 1.73
Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J Biol Chem (1995) 1.70
A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto) Ann Neurol (2000) 1.65
Stress-activated protein kinase-3 interacts with the PDZ domain of alpha1-syntrophin. A mechanism for specific substrate recognition. J Biol Chem (1999) 1.50
Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol (1999) 1.49
The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs. FEBS Lett (1992) 1.45
Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. Biochem J (2000) 1.44
Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci Lett (1999) 1.42
Abnormal tau-containing filaments in neurodegenerative diseases. J Struct Biol (2000) 1.42
Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease. Proc Natl Acad Sci U S A (1990) 1.42
Comparison of the neurofibrillary pathology in Alzheimer's disease and familial presenile dementia with tangles. Acta Neuropathol (1996) 1.39
Tau pathology in a family with dementia and a P301L mutation in tau. J Neuropathol Exp Neurol (1999) 1.38
SAP kinase-3, a new member of the family of mammalian stress-activated protein kinases. FEBS Lett (1996) 1.37
Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci Lett (2000) 1.27
Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment. Acta Neuropathol (1996) 1.27
Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease. Proc Natl Acad Sci U S A (1990) 1.22
The microtubule binding repeats of tau protein assemble into filaments like those found in Alzheimer's disease. FEBS Lett (1992) 1.21
FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10. FEBS Lett (1999) 1.19
Dose-dependent effects of capsaicin on primary sensory neurons in the neonatal rat. J Neurosci (1983) 1.18
Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett (1995) 1.18
Assembly of Alzheimer-like filaments from full-length tau protein. FEBS Lett (1994) 1.18
Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol Psychiatry (1998) 1.17
Structural basis for recognition of the RNA major groove in the tau exon 10 splicing regulatory element by aminoglycoside antibiotics. Nucleic Acids Res (2000) 1.17
Dopamine, norepinephrine and serotonin production by an intestinal carcinoid tumor. Cancer (1980) 1.16
Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett (1996) 1.16
Alternative splicing of synaptotagmins involving transmembrane exon skipping. FEBS Lett (1999) 1.15
Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits. J Neuropathol Exp Neurol (1999) 1.12
Expression of APP in transgenic mice: a comparison of neuron-specific promoters. Neurobiol Aging (1996) 1.12
Nerve growth factor counteracts the neurophysiological and neurochemical effects of chronic sciatic nerve section. Brain Res (1985) 1.10
Correlation between inositol phospholipid hydrolysis and substance P receptors in rat CNS. Nature (1984) 1.09
SKK4, a novel activator of stress-activated protein kinase-1 (SAPK1/JNK). FEBS Lett (1997) 1.08
Familial Parkinson's disease. The awakening of alpha-synuclein. Nature (1997) 1.07
Regulation of alternative splicing of human tau exon 10 by phosphorylation of splicing factors. Mol Cell Neurosci (2001) 1.07
Invited review: Prion-like transmission and spreading of tau pathology. Neuropathol Appl Neurobiol (2015) 1.05
Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem J (1996) 1.04
Tau gene mutation K257T causes a tauopathy similar to Pick's disease. J Neuropathol Exp Neurol (2000) 1.04
The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer's disease. Ann Med (1989) 1.04
Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer's disease. Brain Res (1986) 1.01
A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Ann Neurol (2000) 1.00
AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. Brain Res Mol Brain Res (1996) 1.00
Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Neurogenetics (2000) 1.00
Synaptotagmin V: a novel synaptotagmin isoform expressed in rat brain. FEBS Lett (1995) 0.99
Familial multiple-system tauopathy with presenile dementia is localized to chromosome 17. Am J Hum Genet (1997) 0.99
Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. Genomics (1995) 0.98
The regional distribution and chromatographic characterisation of neurotensin-like immunoreactivity in the rat central nervous system. J Neurochem (1982) 0.98
Requirement of nerve growth factor for development of substance P-containing sensory neurones. Nature (1980) 0.98
Pick's disease associated with the novel Tau gene mutation K369I. Ann Neurol (2001) 0.97
Biochemical effects of antibodies against nerve growth factor on developing and differentiated sympathetic ganglia. Brain Res (1978) 0.96
The nature of the substance P-containing nerve fibres in taste papillae of the rat tongue. Neuroscience (1982) 0.95
Biochemical and anatomical effects of antibodies against nerve growth factor on developing rat sensory ganglia. Proc Natl Acad Sci U S A (1984) 0.95
Neurotensin stimulates inositol phospholipid hydrolysis in rat brain slices. Brain Res (1984) 0.93
Examination of the role of endopeptidase 3.4.24.15 in A beta secretion by human transfected cells. Br J Pharmacol (1997) 0.92
Molecular structure of microtubule-associated protein 2b and 2c from rat brain. J Biol Chem (1990) 0.90
Neurotensin in human small cell lung carcinoma. Br J Cancer (1984) 0.90
Argyrophilic grain disease: widespread hyperphosphorylation of tau protein in limbic neurons. Acta Neuropathol (1997) 0.88
Evidence for neurotensin as a non-adrenergic, non-cholinergic neurotransmitter in guinea pig ileum. Nature (1984) 0.88
Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. Ann N Y Acad Sci (1996) 0.88
Cathepsin D displays in vitro beta-secretase-like specificity. Brain Res (1997) 0.87
Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. Neurosci Lett (1994) 0.86
Tau proteins are abnormally expressed in olfactory epithelium of Alzheimer patients and developmentally regulated in human fetal spinal cord. Exp Neurol (1993) 0.86
The natural osmolyte trimethylamine N-oxide (TMAO) restores the ability of mutant tau to promote microtubule assembly. FEBS Lett (2000) 0.84
ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. Neurosci Lett (1995) 0.84
Use of a heat-stable microtubule-associated protein class-specific antibody to investigate the mechanism of microtubule binding. J Biol Chem (1991) 0.84
The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease. Biochem Pharmacol (1984) 0.83
Phosphorylation of tau by cyclic-AMP-dependent protein kinase. Dementia (1994) 0.83